INSTITUTE FOR HUMAN INFECTIONS & IMMUNITY (IHII)
FY2027 Phased Award Program
OVERVIEW
The purpose of the IHII Phased Award Program is to support multidisciplinary research collaborations at UTMB, leading to a large NIH programmatic grant (P01) submission in FY28 in strategic areas of infectious diseases and immunology (ID-IMM) research. It is expected that the recipient of this bi-phasic award will submit a competitive P01 grant (such as PAR-27-082) in FY2028.
This program is funded by generous support from the McLaughlin Endowment and collaborative institutes and centers at the UTMB. The IHII wants to focus strategically on research ideas that will enhance interdisciplinary, collaborative basic-translational-clinical research, and potentially lead to product/technology development and commercialization. Projects should bring together diverse disciplines to address innovative human health questions relevant to the mission of NIAID.
PHASED AWARD STRUCTURE
This unique program will utilize a bi-phasic, milestone-driven mechanism consisting of a 6-month start-up phase (Phase 1- up to $50,000), followed by a 1-year finalization phase (Phase 2- up to $100,000). Each phase must have clearly defined core milestones that signify the completion of a major project stage/activity. Appropriate completion of Phase 1 milestones must be achieved to secure funding for Phase 2.
ELIGIBILITY
- All UTMB faculty who plan to submit extramural grant applications are encouraged to apply. Proposals from basic, clinical, and translational ID-IMM related fields are welcome. New faculty or those developing new interests related to ID-IMM research are encouraged to seek membership in the IHII before applying.
- Progress reports for past IHII grants will be reviewed to assess the PI’s productivity and return-on-investment.
- The PI and project leaders may not have already received funding for the proposed project from other intramural or extramural sources; all related, pending proposals must be disclosed in your application.
FUNDING (contingent on availability of funds)
- Phase 1 will consist of up to $50,000 and Phase 2 will consist of up to $100,000. Phase 1 milestones must be achieved in order to receive Phase 2 funding.
All funds must be spent by July 30, 2027. Carry-over across fiscal years is not possible due to institutional budgeting requirements.
- It is expected that, when needed, core facilities at the UTMB will be utilized. Funding of research taking place outside of the UTMB campus must be strongly justified.
- Funds may be used for up to 5% of clinical faculty salary support (including tenure-track) but this must be well justified within the project. Funds can be used to support non-tenure track salaries, but cannot be used for non-clinical, tenure-track faculty salaries or for indirect costs.
- Requests for equipment and travel (except where required to collect samples or data) are not justifiable expenses.
STRATEGIC RESEARCH AREAS
We seek to foster collaborative, interdisciplinary research focused on the development and application of multiscale research models to define mechanisms of infection, inform the development of medical interventions, and characterize immune responses and disease trajectories. Areas of interest include:
- Mechanisms of infection and transmission: Elucidate the biological mechanisms underlying pathogen infection and transmission and translate these insights into improved preventive and therapeutic strategies.
- Immune-mediated disease trajectories: Characterize the trajectories of immune-mediated diseases from initiation through progression and/or resolution, including the contributions of the microbiome and infectious agents.
- Inter-disciplinary studies at the intersection of infection and immunity: We encourage interdisciplinary research that:
1) Investigates immune responses to infections and vaccines in infants and young children.
2) Examines how environmental toxins, comorbidities, and other host factors influence immunity to infectious agents and vaccines.
3) Determines whether infections, immune responses, or vaccination accelerate or reverse biological aging.
4) Elucidates interactions among infectious agents, immune responses, and the nervous system in brain aging and neurological disorders.
- Emerging and vector-borne infectious threats: Address emerging challenges posed by vector-borne and other infectious threats. Emphasis is placed on developing innovative diagnostics and surveillance approaches to monitor multi-pathogen infections, transmission, and treatment efficacy.
APPLICATION INSTRUCTIONS
I. An Office of Sponsored Programs Proposal Routing Form must accompany all intramural research grant applications (
OSP Routing Form.pdf)
II. PROPOSAL PACKAGE (maximum six pages for A-D).
A. Title of the proposal
B. Names, affiliation, and expertise of the PI, project leaders and collaborators as relevant to the proposal.
C. A description of how the IHII support will lead to a future P01 submission, such as to PAR-27-082. Include plan and timeline for the P01 submission, as well as a summary of the central unifying theme of the planned P01. Provide brief summaries of the research projects and scientific core(s) that would be anticipated for the P01. Which external collaborators would be included in the P01? Why is the P01 an appropriate mechanism for this research instead of separate R01 submissions?
D. Proposed research plan. Organize the research plan as follows:
1. Specific Aims: State the broad problem and central theme of the planned P01, critical knowledge gap, central hypothesis, and rationale for each aim.
2. Research Strategy:
Significance: Explain the central theme of the planned P01, why the problem matters and how the project addresses it. Describe how the scientific landscape will be shifted or improved if stated objectives are met.
Innovation: Highlight novel concepts, approaches, methodologies, or structural interventions.
Approach: Include preliminary data that establish experimental feasibility or your team’s capability; outline of specific experimental design, methods, statistical analysis; identify expected outcomes, potential pitfalls, and alternatives; address scientific rigor and reproducibility as applicable.
Core Milestones: Clearly propose and justify the Phase 1 core milestones and the Phase 2 core milestones that will be subject to committee review. Milestones should be measurable and indicative of project progress.
E. A list of cited literature. This section is not considered in page limitations.
F. Detailed budget and budget justification for Phase 1 support and a separate detailed budget and justification for Phase 2 support. This section is not considered in page limitations.
G. SciENcv Biosketch of PI and key personnel. This section is not considered in page limitations.
H. ScieENcv Currrent/Pending Support file. Please include active and pending grants or any additional funds that are available to the PI/key personnel from intramural or extramural source. Junior investigators should also list start-up funds. Cite overlap with the proposed project (if any). This section is not considered in page limitations.
PROPOSAL SUBMISSION
Proposals may be submitted by December 21, at 9 AM. Please send a single PDF file to Ms. Marcela Lopez (McLaughlin.IHII@utmb.edu). Please name your file as “LastName-Phased Grant.pdf” (e.g., Smith-Phased Grant.pdf)
APPLICATION REVIEW
The IHII Executive Committee and ad hoc reviewers will evaluate all proposals. Reviewers will be asked to consider the strengths and weaknesses of the proposal, as well as the likelihood that successful completion of the proposed project will lead to a competitive P01 submission.
Awards will be announced by January 4, 2027, depending on the availability of the funds and in accordance with the UTMB fiscal calendar year. Please contact Ms. Marcela Lopez (mblopez@utmb.edu) with questions or for further information.
REPORTING REQUIREMENTS
- Awardees will be asked to submit a Phase 1 progress report summarizing progress of the Phase 1 core milestones and plan for the Phase 2 at the beginning of FY2028. This document will be reviewed by the committee to inform the Phase 2 funding decision.
- Awardees agree by acceptance of funding to include the Institute for Human Infections and Immunity in their affiliations on all publications and presentations arising from the grant, and to acknowledge the Institute for Human Infections and Immunity (and collaborative partners) for financial support.
- The Principal Investigator will be responsible for monitoring the deliverables, progress of the project, and providing a final report at the conclusion of Phase 2 (if awarded). Reports should include status of the study, resources committed, and value created (new manuscripts, disclosures, grants, etc.). The final report will be due 45 days after the end date of the phase 2 project.
- The IHII will expect the submission of a related P01 grant (such as PAR-27-082) in FY2028 for an investigator to be eligible to apply for future IHII awards.